Also, I believe Freud's the one who said "Present me to a normal person and I'll cure him"
Besides, don't react too loudly or you might awaken the 2 mighty gods involved in this analysis: biology(°) and cognitive behaviour(°°).
I guess what it boils down to is about being able to control your anger instead of being it's puppet.
P.S:sorry about the footnotes, I've been standing in line for too long and felt like doing something silly.
1. Principal Investigator, "Valproate in Combination with Lithium Carbonate
for the Maintenance Treatment of Bipolar Patients at High Risk for
Recurrence," Young Investigator Award, 1992-94, National Alliance for
Research on Schizophrenia and Depression, $60,000
2. Co-Principal Investigator, "Valproate in Combination with Lithium
Carbonate for the Maintenance Treatment of Bipolar Patients at High Risk for
Recurrence," 1992-94, Abbott Laboratories, $10,000
3. Investigator, "Family Treatment of Bipolar Disorder," R01 MH48171, Ivan
Miller, Principal Investigator, 9/1/92-2/28/99, National Institute of Mental
Health, $2,196,753
4. Investigator, "A Phase II, Multicenter, Randomized, Parallel-Group, Double-
Blind, Dose-Finding Study of 3 Different Doses of Roxindole vs. Placebo in
Outpatients with Major Depression," Martin B. Keller, Principal Investigator,
6/93-7/94, EM Industries, $93,492
5. Investigator, "Double-Blind Parallel Comparison of Sertraline and
Imipramine in Outpatients with Chronic Major Depression," Martin B.
Keller, Principal Investigator, 4/1/93-3/30/97, Pfizer, $600,000
6. Investigator, "Double-blind Parallel Comparison of Sertraline and
Imipramine in Outpatients with Concurrent DSM-III-R Major Depression
and Dysthymia," Martin B. Keller, Principal Investigator, 4/1/93-3/30/97,
Pfizer, $600,000
7. Investigator, "Fluoxetine vs. Sertraline and Paroxetine in Major Depression:
Comparison of Discontinuation/Emergent Signs and Symptoms," Gabor
Keitner, Principal Investigator, 9/1/96-9/1/97, Eli Lilly, $146,973
8. Investigator, "A Multi-Center Study Comparing the Safety and Efficacy of
Nefazodone HCl to Cognitive Behavioral Therapy – Chronic Depression
(CBT-CD) and Combined Nefazodone HCl and CBT-CD for the Acute,
Continuation, and Maintenance Treatment of Chronic Forms of Depression,"
Martin B. Keller, Principal Investigator, 6/1/96-5/31/99, Bristol Myers Squibb,
$798,000
9. Investigator, "Thyroxine Treatment of the Neurocognitive Side Effects of
Lithium," Independent Investigator Award, Robert Stern, Principal
Investigator, 1997-99, National Alliance for Research on Schizophrenia and
Depression, $92,592
10. Investigator, "Multicenter, Placebo-Controlled Study of Relapse Prevention by
Long-Term Treatment with Remeron in Outpatients with Major Depressive
Episode," Martin B. Keller, Principal Investigator, 9/97-3/99, Organon,
$217,000
11. Principal Investigator, "Lithium plus Valproate for Treatment of Bipolar
Disorder," Department Research Award, 1998-99, Department of Psychiatry
and Human Behavior, Brown University, $11,583
12. Investigator, "Olanzapine versus Placebo in the Treatment of Bipolar
Disorder, Manic or Mixed," Gabor Keitner, Principal Investigator, 2/98-6/99,
Eli Lilly, $279,187
13. Investigator, "Efficacy of a Family Telephone Intervention for Stroke," R01
NS37840, Ivan Miller, Principal Investigator, 9/1/98-8/30/03, National Institute of Neurological Disorders and Stroke, $2,540,523
14. Investigator, "An Eight Week, Multicenter, Parallel-Group, Double-Blind,
Placebo-Controlled Study of St. John's Wort in Outpatients with DSM-IV
Major Depression," Martin B. Keller, Principal Investigator, 9/1/98-8/31/99, Vanderbilt University and Pfizer, $138,300
15. Investigator, "Open Trial of St. John's Wort in the Treatment of Subsyndromal Depression," Ivan Miller, Principal Investigator, 1998-1999, Lifespan, $10,000
16. Investigator, "Integrative Group Treatment for Depression," R21 MH59791 Ivan Miller, Principal Investigator, 4/99-3/02, NIMH, $298,084
17. Investigator, "An Open-Label Randomized Assessment of the Efficacy and
Tolerability Venlafaxine Extended Release in Serotonin-Selective Reuptake
Inhibitor (SSRI) Failure Patients with Major Depression," Gabor Keitner,
Principal Investigator, 6/99-6/00, Wyeth-Ayerst Laboratories, $87,000
18. Investigator, "A Double-Blind Study of Two Doses of LL-759274 versus
Paroxetine Hydrochloride and Placebo in the Treatment of Outpatients with
Major Depressive Disorder," Gabor Keitner, Principal Investigator, 6/99-6/00,
Merck & Co., $221,000
19. Investigator, "Antidepressant Treatment to Reduce HIV Risk Among Injection Drug Users," R01 MH61141, Michael Stein, Principal Investigator, 9/30/99-8/31/03, NIMH $1,169,268
20. Investigator, "The Use of Mirtazapine in Reducing SSRI-Induced Sexual Side
Effects," Gabor Keitner, Principal Investigator, 3/1/00 –current, Yale
University and Organon, $198,000
21. Investigator, "Clinical Trial of Donepezil HCl (Aricept) in Diminishing
Cognitive Impairment Associated with Electroconvulsive Therapy," Robert A. Stern, Principal Investigator, 7/1/00-6/30/02, Pfizer, $136,068
22. Investigator, "Combined Treatment for Depressed Inpatients," R01 MH58866, Ivan Miller, Principal Investigator, 2/15/00-3/1/05, NIMH, $3,289,792
23. Co-investigator, "Antidepressant Treatment to Reduce HIV Risk Among Injection Drug Users," R01 MH61141, Michael Stein, Principal Investigator, 9/28/99-9/27/03, NIMH $1,815,221
24. Co-investigator, "Antidepressant Treatment to Maintain Risk Reduction Among Injection Drug Users," R01 MH62719, Michael Stein, Principal Investigator, 9/30/00-8/31/05, NIMH $2,284,149
25. Co-Principal Investigator, "Collaborative Depression Study," 2R10
MH25478-24, Martin Keller, Principal Investigator, 7/1/98-6/30/03, National
Institute of Mental Health
26. Co-Principal Investigator, "Collaborative Depression Study (no cost extension),"
2R10 MH25478-29, Martin Keller, Principal Investigator, 7/1/03-6/30/04,
National Institute of Mental Health
27. Co-Principal Investigator, "Collaborative Depression Study," 2R10
MH25478-29A2, Martin Keller, Principal Investigator, 7/1/04-6/30/09, National
Institute of Mental Health